Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

NCT05107375 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

299

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronavirus Disease 2019

Interventions

BIOLOGICAL: Tetravalent influenza virus lysis vaccine
BIOLOGICAL: Recombinant new coronavirus vaccine (CHO cell) group

Sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.